Arrow® Seldinger Arterial Catheterization Device Receives FDA Market Clearance
July 24 2017 - 6:45AM
Business Wire
Designed for Risk Reduction, Optimal
Performance, and Patient Safety
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies for critical care and surgery, has announced
today that its Arrow® Seldinger Arterial Catheterization Device
received market clearance from the U.S. Food and Drug
Administration (FDA).
The new Seldinger Arterial Catheterization Device is indicated
for short-term use. The device is designed to improve patient
safety by eliminating confusion of catheter identification, reduce
risk of complications associated with insertion technique, and
provide optimal diagnostics leading to effective treatment for
patients. Multiple sizes are available to provide customization to
each patient, each insertion site, and each application.
“As we continue to discover new and innovative solutions, the
Seldinger Arterial Catheterization Device is now part of our
extensive arterial offering in the U.S. market,” said Jake Newman,
Vice President and General Manager of Teleflex's Vascular Access
Division. “This innovative device is intended to facilitate ease of
insertion and resistance to body collapse1.”
Teleflex expects to launch the Arrow® Seldinger Arterial
Catheterization Device in the United States this year.
To learn more about the Arrow® Vascular portfolio from Teleflex,
please visit teleflex.com/usa/product-areas/vascular-access/.
About Teleflex IncorporatedTeleflex is a global provider
of medical technologies designed to improve the health and quality
of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular and interventional access,
surgical, anesthesia, cardiac care, urology, emergency medicine and
respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For
more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch® and Weck® – trusted brands united by a common
sense of purpose.
Forward-Looking StatementsAny statements contained in
this press release that do not describe historical facts may
constitute forward-looking statements. Any forward-looking
statements contained herein are based on our management's current
beliefs and expectations, but are subject to a number of risks,
uncertainties and changes in circumstances, which may cause actual
results or company actions to differ materially from what is
expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our
filings with the Securities and Exchange Commission, including our
Annual Report on Form 10-K.
References:1. Teleflex. Seldinger Arterial Catheter
Benchtop Studies. Data on File, D011453: 2014.
Teleflex, the Teleflex logo, and Arrow are trademarks or
registered trademarks of Teleflex Incorporated or its affiliates,
in the U.S. and/or other countries.
© 2017 Teleflex Incorporated. All rights reserved. MC-003596
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170724005075/en/
Teleflex IncorporatedJake Elguicze, 610-948-2836Treasurer and
Vice President, Investor Relations
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024